Drug Profile
Research programme: humanised fusion proteins - Sophiris Bio
Alternative Names: HUMxin platform; HUMxin ProgrammeLatest Information Update: 22 Sep 2021
Price :
$50
*
At a glance
- Originator Medicenna Ventures
- Developer Sophiris Bio
- Class Recombinant fusion proteins
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 02 Apr 2012 Protox Therapeutics is now called Sophiris Bio
- 02 Apr 2012 Discontinued for Cancer in Canada (unspecified route)
- 23 Aug 2007 Early research in Cancer in Canada (unspecified route)